Kamal Ghorui
Lord’s Mark Industries Limited has entered into a Technology Transfer Agreement with the Centre for Materials for Electronic Technology (CMET) to manufacture an AI-powered, radiation-free Breast Screening Wearable Device for early detection of breast cancer.India ranks third globally in new breast cancer incidence after China and the US, with the disease accounting for over 26% of all female cancers in the country. The global breast cancer market was valued at USD 4,882.14 million in 2024 and is projected to reach USD 12,880.85 million by 2035 at a CAGR of 9.22%1 . Grand View Research highlights2 diagnostics as the dominant segment driven by early detection demand, while Future Market Insights estimates the screening and diagnostics market at USD 5.05–5.86 billion in 2025, expected to reach USD 10.5–11.36 billion by 2033–20353.The wearable integrates high-precision thermal sensors with AI-driven temperature mapping to identify early-stage abnormalities in a non-invasive, radiation-free manner. The partnership combines CMET’s R&D expertise with Lord’s Mark’s manufacturing scale and distribution strength, accelerating indigenous med-tech innovation.Key features and advantages
- Convenient and infrastructure-light: Usable in comfortable settings with minimal setup across hospitals, clinics, community centers, and homes.
- Non-radiative and painless: Eliminates radiation exposure and discomfort, improving screening compliance.
- Advanced thermal sensors: High-precision temperature mapping powered by AI-driven analytics for real-time insights
- Privacy-first design: Discreetly wearable under clothing, ensuring dignity and user comfort.
- Early abnormality detection: Identifies early-stage thermal irregularities to support timely medical evaluation
- Portable and scalable: Lightweight, mobile solution enabling deployment across urban and underserved regions alike.
The device represents a significant advancement over traditional mammography by eliminating radiation exposure and discomfort, expanding access beyond hospital settings, and delivering reliable AI-driven detection insights.With this initiative, Lord’s Mark reinforces its long-term commitment to advancing accessible, AI-led healthcare solutions, positioning itself at the forefront of scalable preventive diagnostics in India.Sachidanand Upadhyay, Managing Director, Lord’s Mark Industries Limited, commenting on the partnership with CMET, said: “This collaboration marks a defining step in our journey to build globally competitive, indigenous healthcare technologies. By integrating CMET’s scientific expertise with Lord’s Mark’s manufacturing strength, we are enabling a new paradigm in preventive diagnostics—non-invasive, AI-driven, and truly accessible. Our vision is to reduce barriers to early detection and empower women across India with safer, smarter screening solutions. This is not just a product initiative; it is a commitment to scalable, impact-led healthcare innovation.”With this initiative, Lord’s Mark Industries Limited says it aims to strengthen its focus on technology-led healthcare manufacturing, with an emphasis on intelligent, inclusive and impact-driven solutions designed to make early detection safer, simpler and more accessible. The company plans to commercialise the product for large-scale breast cancer screening in India and, over time, expand its availability to international markets through its growing global network. According to the company, the effort is also positioned as part of a broader ambition to take an India-developed healthcare technology to the world.Lord’s Mark Industries Limited says it aims to make the screening solution affordable so that more women in India and abroad can access regular testing. According to the company, the initiative is also intended to support greater awareness around breast cancer and highlight the role of early detection in improving treatment outcomes. The company adds that it expects the product to be available for commercial use globally by the end of the year.For more information, visit the website.References: Disclaimer – The above content is non-editorial, and TIL hereby disclaims any and all warranties, expressed or implied, relating to it, and does not guarantee, vouch for or necessarily endorse any of the content.
